Health Services Research Unit, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.
Value Health. 2013 Jun;16(4):564-73. doi: 10.1016/j.jval.2013.01.006. Epub 2013 Apr 23.
To evaluate the performance of the Mental Component of the Short-Form 12 Health Survey, Version 1(SF-12v1), as a screening measure of depressive disorders.
Data come from the European Study of the Epidemiology of Mental Disorders (ESEMeD), a cross-sectional survey carried out on representative samples of 21,425 individuals from the noninstitutionalized adult general population of six European countries (response rate = 61.2%). The SF-12 was administered and scored according to three algorithms: the "original" method (mental component summary of SF-12 [MCS-12]), the RAND-12 (RAND-12 Mental Health Composite [RAND-12 MHC]), and the Bidemensional Response Process Model 12 mental health score (BRP-12 MHS), based on a two-factor Item Response Theory graded response model. Thirty-day and 12-month depressive disorders (major depressive episode or dysthymia) were assessed with the Composite International Diagnostic Interview, Version 3.0, by using Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria. Receiver operating characteristic curves analysis was carried out, and optimal cutoff points maximizing balance between sensitivity (SN) and specificity (SP) were chosen for the three methods.
Prevalence of 30-day and 12-month depressive disorders in the overall sample was 1.5% and 4.4%, respectively. The area under the curve for 30-day depressive disorders was 0.92, and it decreased to 0.85 for 12-month disorders, regardless of the scoring method. Optimal cutoff for 30-day depressive disorders was 45.6 (SN = 0.86; SP = 0.88) for the MCS-12, 44.5 for the RAND-12 MHC (SN = 0.87, SP = 0.86), and 40.2 for the BRP-12 MHS (SN = 0.87, SP = 0.87). The selected 12-month cutoffs for MCS-12 and RAND-12 MHC were between 4.2 and 5.8 points below the general population means of each country, with SN range 0.67 to 0.78 and SP range 0.77 to 0.87.
The SF-12 yielded acceptable results for detecting both active and recent depressive disorders in general population samples, suggesting that the questionnaire could be used as a useful screening tool for monitoring the prevalence of affective disorders and for targeting treatment and prevention.
评估短式 12 健康调查精神分量表（SF-12v1）作为抑郁障碍筛查手段的性能。
数据来自欧洲精神障碍流行病学研究（ESEMeD），这是一项在来自欧洲六个国家的非住院成年一般人群的代表性样本中进行的横断面调查（应答率=61.2%）。SF-12 根据三种算法进行管理和评分：“原始”方法（SF-12 的精神分量表摘要 [MCS-12]）、RAND-12（RAND-12 心理健康综合评分 [RAND-12 MHC]）和基于双因素项目反应理论等级反应模型的Bidemensional 反应过程模型 12 心理健康评分（BRP-12 MHS）。使用复合国际诊断访谈 3.0 版，根据精神障碍诊断与统计手册第四版标准，评估 30 天和 12 个月的抑郁障碍（重性抑郁发作或心境恶劣）。进行了接收者操作特征曲线分析，并选择了三种方法中灵敏度（SN）和特异性（SP）之间平衡最佳的最优截断点。
总体样本中 30 天和 12 个月抑郁障碍的患病率分别为 1.5%和 4.4%。30 天抑郁障碍的曲线下面积为 0.92，而 12 个月时的曲线下面积降至 0.85，无论评分方法如何。对于 30 天的抑郁障碍，MCS-12 的最佳截断值为 45.6（SN=0.86；SP=0.88），RAND-12 MHC 的最佳截断值为 44.5（SN=0.87，SP=0.86），BRP-12 MHS 的最佳截断值为 40.2（SN=0.87，SP=0.87）。MCS-12 和 RAND-12 MHC 的选定 12 个月截断值在每个国家的一般人群均值以下 4.2 至 5.8 分之间，SN 范围为 0.67 至 0.78，SP 范围为 0.77 至 0.87。
SF-12 对一般人群样本中活跃和近期抑郁障碍的检测结果令人满意，表明该问卷可用作监测情感障碍患病率的有用筛查工具，并可作为治疗和预防的目标。
